The specificity of severe ADAMTS-13 deficiency (<5%) in distinguishing acute TTP from HUS is 90%.36,71 This differentiation should be performed rapidly for the appropriate initiation of PEX for TTP and eculizumab for aHUS.72 The gene discussed is ADAMTS13; the disease is hemolytic-uremic syndrome.